+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Resorbable Vascular Scaffold Market by Indication, Material, End User, Distribution Channel, Scaffold Diameter, Scaffold Length - Global Forecast to 2030- Product Image
Resorbable Vascular Scaffold Market by Indication, Material, End User, Distribution Channel, Scaffold Diameter, Scaffold Length - Global Forecast to 2030- Product Image
Sale

Resorbable Vascular Scaffold Market by Indication, Material, End User, Distribution Channel, Scaffold Diameter, Scaffold Length - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012364
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Resorbable Vascular Scaffold Market grew from USD 576.57 million in 2024 to USD 656.95 million in 2025. It is expected to continue growing at a CAGR of 13.82%, reaching USD 1.25 billion by 2030.

Introducing the Evolving Field of Resorbable Vascular Scaffolds

The resorbable vascular scaffold arena is at the cusp of a new era, driven by the quest for improved patient outcomes and streamlined procedural workflows. Unlike permanent metallic stents, resorbable technologies are designed to provide temporary vessel support and dissolve over time, minimizing long-term complications and offering a paradigm shift in interventional cardiology and vascular medicine. This introduction lays the foundation for a detailed exploration of the market forces, technological breakthroughs, and strategic imperatives that define this evolving segment.

This executive summary distills critical findings from extensive primary and secondary research, underscoring how shifting clinical preferences, regulatory milestones, and material science innovations are reshaping the field. By synthesizing expert interviews, peer-reviewed literature, and real-world usage data, this report empowers stakeholders to navigate complexity and identify areas for investment, partnership, and growth. The subsequent sections present an integrated analysis of market dynamics, segmentation, regional variances, corporate strategies, and actionable recommendations, all aimed at facilitating informed decision-making.

Unveiling Transformative Shifts That Are Redefining Patient Care

A wave of innovation is transforming the resorbable vascular scaffold landscape, from breakthroughs in polymer chemistry to advances in bioengineering. Developers are leveraging magnesium alloys that exhibit controlled absorption profiles and enhanced radial strength, while polylactic acid formulations have achieved refined degradation rates tailored to diverse clinical scenarios. These material breakthroughs coincide with the adoption of next-generation imaging modalities, enabling physicians to monitor scaffold integrity and vessel healing with unprecedented clarity.

Concurrently, regulatory bodies have granted approvals in key markets, signaling growing confidence in scaffold safety and performance. Health systems are increasingly embracing minimally invasive interventions that reduce patient downtime and long-term complications. These transformative shifts are converging to redefine procedural protocols, expand therapeutic indications, and elevate the role of resorbable scaffolds as a cornerstone of patient-centric care.

Assessing the Ripple Effects of United States Tariffs in 2025

The introduction of tariffs on imported components and raw materials in 2025 has created a ripple effect across the resorbable scaffold supply chain. Manufacturers are reassessing sourcing strategies to mitigate cost pressures, exploring nearshoring opportunities and forging new alliances with regional suppliers. These adjustments are fostering resilience but also introduce complexities around quality assurance and lead times, as domestic capacity scales to meet demand.

Moreover, the tariff environment is prompting a reexamination of procurement models for healthcare providers. Hospitals and cardiac centers are negotiating long-term agreements to stabilize pricing, while ambulatory surgical centers are evaluating collaborative purchasing consortia. These adaptations underscore the importance of supply chain agility and strategic foresight in maintaining access to advanced scaffold technologies without compromising cost efficiency.

Unlocking Insights from Core Market Segmentation Dynamics

A nuanced understanding of clinical applications reveals that coronary artery disease remains the primary focus for scaffold deployment, with acute coronary syndrome and stable angina driving differentiated treatment protocols. At the same time, resorbable scaffolds are making inroads into peripheral arterial disease management, offering novel solutions for patients with claudication and critical limb ischemia. These indication-based variations inform product design and post-procedural care pathways.

Material choice further refines market positioning, as magnesium-based scaffolds appeal to practitioners seeking rapid endothelialization, whereas polylactic acid variants address scenarios where extended vessel support is essential. End users, from high-volume hospitals to specialized cardiac centers and outpatient surgical suites, exhibit distinct procurement preferences and utilization rates. Distribution channels also play a critical role, with direct sales fostering closer partnerships between manufacturers and key accounts, while distributors extend reach into emerging hospitals and regional clinics.

Scaffold dimensions represent an additional layer of segmentation, with devices under three millimeters in diameter tailored for smaller coronary vessels and those three millimeters or above suited for larger arteries. Length variations-from less than eighteen millimeters to segments exceeding twenty-eight millimeters-accommodate diverse lesion profiles, enabling clinicians to optimize scaffold selection for each patient’s anatomical and clinical context.

Navigating Regional Variances in Adoption and Growth Patterns

In the Americas, advanced reimbursement frameworks and a strong focus on minimally invasive procedures have accelerated adoption of resorbable scaffolds, particularly in leading cardiac centers. Patient awareness initiatives and physician training programs further support market penetration, creating a mature environment receptive to incremental product enhancements. Meanwhile, Europe, Middle East & Africa present a heterogeneous landscape: Western Europe’s stringent clinical guidelines and robust funding mechanisms contrast with emerging markets in the Middle East and Africa, where infrastructure development and capacity building are pivotal for future growth.

The Asia-Pacific region is characterized by rapid technology uptake, driven by expanding interventional cardiology services in key markets. Government initiatives aimed at improving healthcare access, coupled with a growing demographic burden of cardiovascular disease, are fueling demand across hospitals and ambulatory settings. However, localized regulatory pathways and variable reimbursement policies require tailored market entry strategies, underscoring the need for regional partnerships and customization of training and support offerings.

Profiling Key Players Driving Innovation and Competitive Edge

Leading corporations are investing heavily in research and development to strengthen their scaffold pipelines and secure intellectual property. Strategic partnerships between device makers and material science firms are accelerating innovation, while acquisitions of niche technology providers are broadening portfolios. Collaborative efforts with academic institutions and clinical trial networks are generating robust clinical evidence, enhancing product credibility among interventional cardiologists.

Smaller specialized players are differentiating through agility, rapidly iterating design enhancements and focusing on underserved indications such as peripheral arterial applications. These companies often leverage licensing agreements to access advanced polymers and metallic alloys, enabling them to compete on performance attributes. Competitive dynamics are also shaped by the emergence of service-oriented models, where post-market surveillance and digital health solutions complement core scaffold offerings, fostering deeper customer engagement.

Strategic Recommendations to Capitalize on Emerging Opportunities

Industry leaders should prioritize diversification of their manufacturing footprint to navigate tariff volatility and ensure uninterrupted supply of critical scaffold components. Establishing regional production hubs will not only mitigate cost fluctuations but also enhance responsiveness to evolving regulatory requirements. Organizations should also deepen collaborations with material innovators, exploring hybrid polymer-metal constructs that combine the best properties of both approaches.

Furthermore, cultivating strategic alliances with healthcare providers will be essential to co-design training programs and evidence-generation studies, accelerating clinical acceptance. Embracing digital platforms for procedural planning and long-term patient follow-up can create value-added services, fostering loyalty and differentiating offerings. Finally, companies must monitor regional policy shifts and engage proactively with regulatory agencies to shape guidelines that support timely scaffold approvals and broad market access.

Ensuring Rigor Through a Robust Multi-Method Research Approach

Our analysis synthesizes data from a combination of primary interviews with leading interventional cardiologists, vascular surgeons and procurement specialists, alongside comprehensive reviews of peer-reviewed journals, regulatory filings and industry reports. Secondary research encompassed public domain sources, patent databases and corporate disclosures to ensure a multi-angle perspective on technological advancements and competitive dynamics.

Quantitative insights were validated through triangulation across multiple data points, while qualitative findings were enriched by expert roundtables and advisory board consultations. The methodology emphasizes transparency and reproducibility, with documented protocols for data collection, coding and analysis. This rigorous approach ensures that our conclusions and recommendations rest on a solid foundation of empirical evidence and domain expertise.

Synthesizing Critical Insights for Informed Decision-Making

In summary, the resorbable vascular scaffold market is undergoing a significant transformation driven by material science breakthroughs, shifting clinical preferences and evolving policy landscapes. Segmentation analysis highlights diverse opportunities across indications, materials, end users and device dimensions, while regional insights reveal distinct market dynamics that require tailored strategies. Competitive activity underscores the importance of innovation partnerships, service integration and strategic positioning to achieve sustainable growth.

By implementing the recommendations outlined herein, stakeholders can navigate tariff pressures, regulatory complexities and fragmentation in adoption rates. The convergence of advanced manufacturing techniques, digital health integration and evidence-based clinical adoption sets the stage for resorbable scaffolds to redefine patient care. Decision-makers who leverage these insights will be well-positioned to capture emerging opportunities and establish leadership in this dynamic market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Coronary Artery Disease
      • Acute Coronary Syndrome
      • Stable Angina
    • Peripheral Arterial Disease
      • Claudication
      • Critical Limb Ischemia
  • Material
    • Magnesium
    • Polylactic Acid
  • End User
    • Ambulatory Surgical Centers
    • Cardiac Centers
    • Hospitals
  • Distribution Channel
    • Direct Sales
    • Distributor
  • Scaffold Diameter
    • Less Than 3 Millimeter
    • Three Millimeter And Above
  • Scaffold Length
    • Eighteen To Twenty Eight Millimeter
    • Greater Than Twenty Eight Millimeter
    • Less Than Eighteen Millimeter
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Terumo Corporation
  • Meril Life Sciences Private Limited
  • Elixir Medical Corporation
  • Xeltis AG
  • Amaran Cardiovascular LLC
  • Cardionovum GmbH
  • MicroPort Scientific Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Resorbable Vascular Scaffold Market, by Indication
8.1. Introduction
8.2. Coronary Artery Disease
8.2.1. Acute Coronary Syndrome
8.2.2. Stable Angina
8.3. Peripheral Arterial Disease
8.3.1. Claudication
8.3.2. Critical Limb Ischemia
9. Resorbable Vascular Scaffold Market, by Material
9.1. Introduction
9.2. Magnesium
9.3. Polylactic Acid
10. Resorbable Vascular Scaffold Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Cardiac Centers
10.4. Hospitals
11. Resorbable Vascular Scaffold Market, by Distribution Channel
11.1. Introduction
11.2. Direct Sales
11.3. Distributor
12. Resorbable Vascular Scaffold Market, by Scaffold Diameter
12.1. Introduction
12.2. Less Than 3 Millimeter
12.3. Three Millimeter And Above
13. Resorbable Vascular Scaffold Market, by Scaffold Length
13.1. Introduction
13.2. Eighteen To Twenty Eight Millimeter
13.3. Greater Than Twenty Eight Millimeter
13.4. Less Than Eighteen Millimeter
14. Americas Resorbable Vascular Scaffold Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Resorbable Vascular Scaffold Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Resorbable Vascular Scaffold Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. Boston Scientific Corporation
17.3.3. Biotronik SE & Co. KG
17.3.4. Terumo Corporation
17.3.5. Meril Life Sciences Private Limited
17.3.6. Elixir Medical Corporation
17.3.7. Xeltis AG
17.3.8. Amaran Cardiovascular LLC
17.3.9. Cardionovum GmbH
17.3.10. MicroPort Scientific Corporation
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RESORBABLE VASCULAR SCAFFOLD MARKET MULTI-CURRENCY
FIGURE 2. RESORBABLE VASCULAR SCAFFOLD MARKET MULTI-LANGUAGE
FIGURE 3. RESORBABLE VASCULAR SCAFFOLD MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. RESORBABLE VASCULAR SCAFFOLD MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. RESORBABLE VASCULAR SCAFFOLD MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESORBABLE VASCULAR SCAFFOLD MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY ACUTE CORONARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MAGNESIUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY POLYLACTIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN 3 MILLIMETER, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY THREE MILLIMETER AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY EIGHTEEN TO TWENTY EIGHT MILLIMETER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY GREATER THAN TWENTY EIGHT MILLIMETER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY LESS THAN EIGHTEEN MILLIMETER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 52. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 53. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 54. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 57. CANADA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 58. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 62. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 65. MEXICO RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 99. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 103. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 106. GERMANY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 107. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 109. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 110. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 111. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 114. FRANCE RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 123. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 125. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 126. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 127. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 129. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 130. ITALY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 131. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 133. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 135. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 138. SPAIN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 163. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 165. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 166. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 167. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 170. DENMARK RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 179. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 181. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 182. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 183. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 185. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 186. QATAR RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 187. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 189. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 191. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 194. FINLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 195. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 211. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 213. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 215. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 218. EGYPT RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 219. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 223. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 226. TURKEY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 227. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 235. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 236. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 237. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 238. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 239. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 242. NORWAY RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 243. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 244. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 245. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 246. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 247. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 250. POLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 251. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 268. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 270. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 271. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 272. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 275. CHINA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 276. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 277. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 278. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 279. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 280. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 283. INDIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 284. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 286. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 287. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 288. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 291. JAPAN RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 292. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD DIAMETER, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY SCAFFOLD LENGTH, 2018-2030 (USD MILLION)
TABLE 300. SOUTH KOREA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY PERIPHERAL ARTERIAL DISEASE, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY MATERIAL, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA RESORBABLE VASCULAR SCAFFOLD MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Resorbable Vascular Scaffold market report include:
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Terumo Corporation
  • Meril Life Sciences Private Limited
  • Elixir Medical Corporation
  • Xeltis AG
  • Amaran Cardiovascular LLC
  • Cardionovum GmbH
  • MicroPort Scientific Corporation

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 656.95 Million
Forecasted Market Value ( USD ) by 2030 $ 1250 Million
Compound Annual Growth Rate13.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Resorbable Vascular Scaffolds Global Market Report 2025 - Product Image

Resorbable Vascular Scaffolds Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Resorbable Vascular Scaffolds - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Resorbable Vascular Scaffolds - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Bioresorbable Vascular Scaffold Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Bioresorbable Vascular Scaffold Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 195 Pages
  • Global
From
Bioresorbable Vascular Scaffolds - Global Strategic Business Report - Product Image

Bioresorbable Vascular Scaffolds - Global Strategic Business Report

  • Report
  • 265 Pages
  • Global
From
Bioresorbable Vascular Scaffold Market Size, Share & Trends Analysis Report by Application (Peripheral Artery, Coronary Artery), End-use ((Hospitals, Ambulatory Care Centers, Specialty Clinics), Region, and Segment Forecasts, 2024-2030 - Product Image

Bioresorbable Vascular Scaffold Market Size, Share & Trends Analysis Report by Application (Peripheral Artery, Coronary Artery), End-use ((Hospitals, Ambulatory Care Centers, Specialty Clinics), Region, and Segment Forecasts, 2024-2030

  • Report
  • 145 Pages
  • Global
From

About the Resorbable Vascular Scaffold Market

The Resorbable Vascular Scaffold (RVS) market is a segment of the Cardiovascular Devices industry. RVS are medical devices used to treat coronary artery disease, a condition caused by the narrowing of the arteries that supply blood to the heart. RVS are designed to be implanted in the artery and gradually dissolve over time, allowing the artery to return to its natural state. This technology has been shown to reduce the risk of restenosis, a condition in which the artery becomes narrowed again after treatment. RVS are becoming increasingly popular due to their ability to reduce the risk of restenosis and the fact that they do not require a second procedure to remove the device. Additionally, RVS are less invasive than traditional stents, which require a larger incision and a longer recovery time. Some companies in the RVS market include Abbott, Biotronik, Boston Scientific, Medtronic, and Terumo. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.